Dr. Bridwell will review the patient profile selection for PSMA imaging and how PSMA imaging will benefit patients as well as where theranostics fits in the prostate cancer space. Phyllis Hoelsworth will then review marketing strategies and best practices for building a successful PSMA program.
In this session, Dr. Bridwell will describe the biodistribution of DCFPyl imaging (F-18 PSMA) to help you to understand the technical maneuvers that can be done to improve the sensitivity to detect pelvic disease and distant metastatic disease. He will also describe the most important clinical characteristics that may impact the sensitivity of the study to include medications, uptake time and type of patient being imaged. Finally, he will outline the important questions to ask the patient prior to the scanning process